EP Patent

EP1332757A1 — Efavirenz compressed tablet formulation

Assigned to Merck Sharp and Dohme LLC · Expires 2003-08-06 · 23y expired

What this patent protects

This invention relates to a 50% drug loaded compressed tablet formulation for efavirenz. Efavirenz is a non-nucleoside reverse transcriptase inhibitor being studied clinically for use in the treatment of HIV infections and AIDS.

USPTO Abstract

This invention relates to a 50% drug loaded compressed tablet formulation for efavirenz. Efavirenz is a non-nucleoside reverse transcriptase inhibitor being studied clinically for use in the treatment of HIV infections and AIDS.

Drugs covered by this patent

Patent Metadata

Patent number
EP1332757A1
Jurisdiction
EP
Classification
—
Expires
2003-08-06
Drug substance claim
No
Drug product claim
No
Assignee
Merck Sharp and Dohme LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.